Short description
Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Description
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Hayward, California, United States, North America
Founded on
January 1, 2004
Exited on
June 28, 2018
Went public on
June 28, 2018
Stock symbol
ANTH
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$56378 - 90123
Sign in for full access
Investors
Cannot Access, Cannot Access, Nopepepe, Uh Ohhhh, Absolutely Noaccess, Noaccess, Cannot Access, Blurry Noaccess, Uh Ohhhh, Nopepepe, Nopepepe
Sign in for full access
Founders
Paul F. Truex